Candicidin: physiologic effect on prostate.
In a double-blind study, candicidin therapy resulted in over-all clinical improvement of benign prostatic hypertrophy symptoms in 78.1 per cent of treated patients compared with 10 per cent for patients given a placebo. Histologic review of prostates of candicidin-treated patients showed more stroma relative to the epithelium. The epithelium was less active with more cuboidal than columnar cells. There were fewer papillary infoldings, and the epithelium contained more true cysts than did the prostates of patients given a placebo. Urinary testosterone, 17-ketosteroids, 17-hydroxycorticosteroids, and serum androgen, follicle-stimulating hormones, and corticosteroid levels ramained within normal values with candicidin therapy.
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000935:Antifungal Agents / Q000627:therapeutic use*; D002174:Candicidin / Q000627:therapeutic use*; D002940:Circadian Rhythm / Q000187:drug effects; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D010919:Placebos; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D013739:Testosterone / Q000097:blood; D014555:Urination Disorders / Q000209:etiology
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D000935:Antifungal Agents; D010919:Placebos; D002174:Candicidin; D013739:Testosterone; D005640:Follicle Stimulating Hormone; D003404:Creatinine; D006854:Hydrocortisone